Pharmacogenetics and outcome with antipsychotic drugs
| Autor: | Arun K. Tiwari, Daniel J. Müller, Tahireh A. Shams, Jennie G. Pouget |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Side effect business.industry medicine.medical_treatment Translational research Heritability medicine.disease 3. Good health Schizophrenia medicine Personalized medicine Antipsychotic business Intensive care medicine Psychiatry Selection (genetic algorithm) Pharmacogenetics |
| Zdroj: | Dialogues in Clinical Neuroscience. 16:555-566 |
| ISSN: | 1958-5969 |
| DOI: | 10.31887/dcns.2014.16.4/jpouget |
| Popis: | Antipsychotic medications are the gold-standard treatment for schizophrenia, and are often prescribed for other mental conditions. However, the efficacy and side-effect profiles of these drugs are heterogeneous, with large interindividual variability. As a result, treatment selection remains a largely trial-and-error process, with many failed treatment regimens endured before finding a tolerable balance between symptom management and side effects. Much of the interindividual variability in response and side effects is due to genetic factors (heritability, h(2)~ 0.60-0.80). Pharmacogenetics is an emerging field that holds the potential to facilitate the selection of the best medication for a particular patient, based on his or her genetic information. In this review we discuss the most promising genetic markers of antipsychotic treatment outcomes, and present current translational research efforts that aim to bring these pharmacogenetic findings to the clinic in the near future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|